A5050747933- Migraine and Headache Studies
- Sympathectomy and Hyperhidrosis Treatments
- Trigeminal Neuralgia and Treatments
- Alzheimer's disease research and treatments
- Olfactory and Sensory Function Studies
- Cholinesterase and Neurodegenerative Diseases
- Cerebrospinal fluid and hydrocephalus
- Dementia and Cognitive Impairment Research
- Autism Spectrum Disorder Research
- Neuroendocrine regulation and behavior
- Obsessive-Compulsive Spectrum Disorders
- Computational Drug Discovery Methods
- Tryptophan and brain disorders
- Infant Development and Preterm Care
- Attention Deficit Hyperactivity Disorder
- Pharmacological Effects and Toxicity Studies
- Health Systems, Economic Evaluations, Quality of Life
- Ophthalmology and Eye Disorders
- Neurological Complications and Syndromes
Roche (United Kingdom)
2015-2022
Weatherford (United Kingdom)
2000
Wellcome Library
1998-1999
CNS Research (United States)
1995
University of Göttingen
1994
Glostrup Hospital
1994
Royal Victoria Infirmary
1994
Oxford Research Group
1994
Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed efficacy safety of gantenerumab in prodromal Alzheimer's disease (AD). this randomized, double-blind, placebo-controlled phase III study, investigated over 2 years. Patients were randomized to 105 mg or 225 placebo every 4 weeks subcutaneous injection. The primary endpoint was change from baseline week 104...
This double-blind, placebo-controlled, multicenter, parallel-group study assessed whether subcutaneous sumatriptan administered during the migraine aura would prolong or modify and prevent delay development of headache. One hundred seventy-one patients (88 receiving 6 mg sumatriptan, 83 placebo) treated a single attack with typical at home, by self-injection. The median duration following first injection was 25 minutes for group 30 placebo (NS). symptom profile similar two treatment groups....
Oral sumatriptan in a dose of 100 mg aborts about 60% migraine attacks within 2 h, but the headache may recur 24 h. We investigated: (i) incidence recurrence after oral (ii) whether second tablet at h increases initial efficacy and/or (iii) prevents and (iv) further treats recurrence. In randomized parallel-group clinical trial, 1246 patients treated one to three (with or without aura), with sumatriptan. Two hours later they all took double-blind table (group I) placebo II). Patients who...
We compared the efficacy and safety of subcutaneous (SC) sumatriptan (6 mg) with that dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 in acute treatment migraine. Two hundred sixty-six adult migraineurs (International Headache Society criteria) completed a multicenter, double-blind, double-dummy, cross-over study. Patients took SC for one attack DHE other random order. Data from both periods show at all time points 15 minutes, was significantly better than providing headache relief...
A multinational, multicentre, randomised, double-blind, double-dummy, crossover study (368 patients treating two attacks) was conducted to compare the efficacy and tolerability of sumatriptan nasal spray (20 mg) with dihydroergotamine (DHE) (1 mg plus optional 1 mg). At primary time point 60 minutes after dosing, significantly more obtained headache relief (change from moderate or severe none mild) treatment than DHE (53% sumatriptan, 41% DHE, p < 0.001). Significantly reported nausea at...
Abstract Background Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that characterized by the core symptoms of social communication difficulties restricted repetitive behaviors. At present, there an unmet medical need for therapies to ameliorate these in order improve quality life autistic individuals. However, several challenges are currently faced ASD community relating development pharmacotherapies, namely conduct clinical trials. Balovaptan V1a...
This multicentre, randomized, double‐blind, placebo‐controlled, parallel group dose‐ranging study compared the efficacy and tolerability of four doses sumatriptan nasal spray (2.5, 5, 10 20 mg) with a placebo, in acute treatment single migraine attack. In total, 544 patients received medication as one nostril, to treat attack clinic. Efficacy assessments included measurement headache severity, clinical disability, presence/absence associated symptoms. The incidence recurrence was also...
SCarlet RoAD (NCT01224106; WN25203), a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-year study of gantenerumab in prodromal AD, was the first global registration-enabling using biomarker screening for entry and single clinical endpoint outcome. Dosing terminated December 2014 following pre-planned futility analysis; patients continue to be followed. Efficacy data completers (n=312) all ITT safety (n=797) are presented. Patients were 50–85 years old with MMSE scores...
Success of clinical trials targeting amyloid pathology requires the identification homogenous subgroups with cognitive problems characteristic early dementia and underlying pathology. The presence βAmyloid in cerebrospinal fluid (CSF Aβ) has been used screening for trials. To minimize use such diagnostics, inexpensive non-invasive prescreening tools is critical. This study explores utility measures predicting CSF Aβ status phase a large-scale trial prodromal Alzheimer’s disease. Data were...
The anti-amyloid beta (Aβ) monoclonal antibody gantenerumab is in late-phase clinical development for early (prodromal-to-mild) Alzheimer’s disease (AD). SKYLINE an upcoming Phase III multicentre, ran- domised, parallel-group, double-blind, placebo-controlled secondary prevention study, evaluating the efficacy and safety of subcutaneous participants at risk for, or earliest stages of, AD. will enrol ~1,200 cognitively unimpaired participants, aged 60–80, with confirmed Aβ pathology...